Pharma Raises Concerns About Draft EU GDP Guideline
This article was originally published in The Gold Sheet
Executive Summary
The European Commission needs to fine tune its good distribution practices (GDP) guideline, the pharmaceutical industry said in comments on a proposed draft revision. Key issues include segregating EU and non-EU product, transportation vs. storage conditions, applicability to investigational products and time limits for transportation hubs.